One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

In the period 2014-2020, approximately 22 percent of liver cancer patients in the United States survived a period of at least five years after diagnosis. This statistic shows the 5-year relative cancer survival rates in the United States for the period 2014-2020, by type of cancer.

This table contains 600 series, with data for years 1997 - 1997 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (15 items: Canada; Prince Edward Island; Newfoundland and Labrador; Nova Scotia ...), Sex (3 items: Both sexes; Females; Males ...), Selected sites of cancer (ICD-9) (4 items: Colorectal cancer; Prostate cancer; Lung cancer; Female breast cancer ...), Characteristics (5 items: Relative survival rate for cancer; High 95% confidence interval; relative survival rate for cancer; Number of cases; Low 95% confidence interval; relative survival rate for cancer ...).

In the period 2014-2020, around 69 percent of cancer patients surveyed between 2014 and 2020 from all ethnic groups survived a period of at least 5 years after diagnosis. This statistic shows the 5-year relative cancer survival rates in the U.S., by ethnic group, in periods between 1975 and 2020.

Cancer survival statistics are typically expressed as the proportion of patients alive at some point subsequent to the diagnosis of their cancer. Statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer.

This statistic displays the five-year survival rate in children with diagnosed cancer, by selected locations, time periods, and type of cancer. In Australia, children with leukaemias had a five-year chance of survival of over 80 percent in the measured period 1997-2006. In comparison, Chinese children with leukaemias in Shanghai had a chance of little more than 50 percent to survive five years (measured in the period 2002-2005).

This bulletin presents the latest one- and five-year age-standardised net survival estimates for adults (aged 15-99 years) diagnosed in England with one of the 21 most common cancers. These cancers comprise over 90% of all newly diagnosed cancers. Source agency: Office for National Statistics Designation: National Statistics Language: English Alternative title: Cancer survival rates

ObjectiveAccessibility to quality healthcare, histopathology of tumor, tumor stage and geographical location influence survival rates. Comprehending the bases of these differences in cervical cancer survival rate, as well as the variables linked to poor prognosis, is critical to improving survival. We aimed to perform the first thorough meta-analysis and systematic review of cervical cancer survival times in Africa based on race, histopathology, geographical location and age.Methods and materialsMajor electronic databases were searched for articles published about cervical cancer survival rate in Africa. The eligible studies involved studies which reported 1-year, 3-year or 5-year overall survival (OS), disease-free survival (DFS) and/or locoregional recurrence (LRR) rate of cervical cancer patients living in Africa. Two reviewers independently chose the studies and evaluated the quality of the selected publications, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA-P). We used random effects analysis to pooled the survival rate across studies and heterogeneity was explored via sub-group and meta-regression analyses. A leave-one-out sensitivity analysis was undertaken, as well as the reporting bias assessment. Our findings were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA-P).ResultsA total of 16,122 women with cervical cancer were covered in the 45 articles (59 studies), with research sample sizes ranging from 22 to 1,059 (median = 187.5). The five-year overall survival (OS) rate was 40.9% (95% CI: 35.5–46.5%). The five-year OS rate ranged from 3.9% (95% CI: 1.9–8.0%) in Malawi to as high as 76.1% (95% CI: 66.3–83.7%) in Ghana. The five-year disease-free survival rate was 66.2% (95% CI: 44.2–82.8%) while the five-year locoregional rate survival was 57.0% (95% CI: 41.4–88.7%).ConclusionTo enhance cervical cancer survival, geographical and racial group health promotion measures, as well as prospective genetic investigations, are critically required.

This presents the latest one- and five-year age-standardised relative survival rates for cancers of the bladder, breast (in women), cervix, colon, lung, oesophagus, prostate and stomach with data for the government office regions (GOR) and strategic health authorities (SHA).

Source agency: Office for National Statistics

Designation: National Statistics

Language: English

Alternative title: Cancer survival in England by Health Authority

Survival estimates for children (aged 0 to 14 years) diagnosed with cancer in England from 2001 to 2017.

In 2022, thyroid cancer had the highest five-year relative survival rate in South Korea, with 100.1 percent. The lowest relative survival rate was among pancreatic cancer patients, at only 16.5 percent. Cancerous neoplasms are the leading cause of death in South Korea, particularly in people 40 years and older.

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024 Cancer Mortality Rate - This indicator shows the age-adjusted mortality rate from cancer (per 100,000 population). Maryland’s age adjusted cancer mortality rate is higher than the US cancer mortality rate. Cancer impacts people across all population groups, however wide racial disparities exist. Link to Data Details

Update 2 March 2023: Following the merger of NHS Digital and NHS England on 1st February 2023 we are reviewing the future presentation of the NHS Outcomes Framework indicators. As part of this review, the annual publication which was due to be released in March 2023 has been delayed. Further announcements about this dataset will be made on this page in due course. A measure of the number of adults diagnosed with any type of cancer in a year who are still alive five years after diagnosis. This indicator attempts to capture the success of the NHS in preventing people from dying once they have been diagnosed with any type of cancer. As of May 2020, please refer to the data tables published by Public Health England (PHE). This publication is released on an annual basis. A link to the PHE publications, within which the data is held, is available via the resource link below. On the publication page select the ‘Data Tables index of cancer survival 20xx to 20xx’. The data for this indicator is available by applying suitable filters to the dataset contained within the 'Data_Complete’ tab. Legacy unique identifier: P01735

One-year and five-year relative survival estimates for adult patients diagnosed with one of eight cancers in England. Results are presented by Government Office Region, Strategic Health Authority and Cancer Network.

Source agency: Office for National Statistics

Designation: Supporting material

Language: English

Alternative title: Cancer Survival by GOR, SHA and Cancer Network

Age-standardized provincial estimates of five-year net survival for 11 types of cancer. Net survival refers to the survival probability that would be observed in the hypothetical situation where the cancer of interest is the only possible cause of death.

Smoothed life tables for use in cancer survival, by sex, index of multiple deprivation, age and region of England.

ABSTRACT OBJECTIVE To analyze inequalities in incidence, mortality, and estimated survival for neoplasms in men according to social vulnerability. METHODS Analysis of cases and deaths of all neoplasms and the five most common in men aged 30 years or older in the city of Campinas (SP), between 2010 and 2014, using data from the Population-Based Cancer Registry (RCBP) and the Mortality Information System (SIM). The areas of residence were grouped into five social vulnerability strata (SVS) using São Paulo Social Vulnerability Index. For each SVS, age-standardized incidence and mortality rates were calculated. A five-year survival proxy was calculated by complementing the ratio of the mortality rate to the incidence rate. Inequalities between strata were measured by the ratios between rates, the relative inequality index (RII) and the angular inequality index (AII). RESULTS RII revealed that the incidence of all neoplasms (0.66, 95%CI 0.62–0.69) and colorectal and lung cancers were lower among the most socially vulnerable, who presented a higher incidence of stomach and oral cavity cancer. Mortality rates for stomach, oral cavity, prostate and all types of cancer were higher in the most vulnerable segments, with no differences in mortality for colorectal and lung cancer. Survival was lower in the most social vulnerable stratum for all types of cancer studied. AII showed excess cases in the least vulnerable and deaths in the most vulnerable. Social inequalities were different depending on the tumor location and the indicator analyzed. CONCLUSION There is a trend of reversal of inequalities between incidence-mortality and incidence-survival, and the most social vulnerable segment presents lower survival rates for the types of cancer, pointing to the existence of inequality in access to early diagnosis and effective and timely treatment.

SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

BackgroundBreast cancer (BC), as a leading cause of cancer mortality in women, demands robust prediction models for early diagnosis and personalized treatment. Artificial Intelligence (AI) and Machine Learning (ML) algorithms offer promising solutions for automated survival prediction, driving this study’s systematic review and meta-analysis.MethodsThree online databases (Web of Science, PubMed, and Scopus) were comprehensively searched (January 2016-August 2023) using key terms (“Breast Cancer”, “Survival Prediction”, and “Machine Learning”) and their synonyms. Original articles applying ML algorithms for BC survival prediction using clinical data were included. The quality of studies was assessed via the Qiao Quality Assessment tool.ResultsAmongst 140 identified articles, 32 met the eligibility criteria. Analyzed ML methods achieved a mean validation accuracy of 89.73%. Hybrid models, combining traditional and modern ML techniques, were mostly considered to predict survival rates (40.62%). Supervised learning was the dominant ML paradigm (75%). Common ML methodologies included pre-processing, feature extraction, dimensionality reduction, and classification. Deep Learning (DL), particularly Convolutional Neural Networks (CNNs), emerged as the preferred modern algorithm within these methodologies. Notably, 81.25% of studies relied on internal validation, primarily using K-fold cross-validation and train/test split strategies.ConclusionThe findings underscore the significant potential of AI-based algorithms in enhancing the accuracy of BC survival predictions. However, to ensure the robustness and generalizability of these predictive models, future research should emphasize the importance of rigorous external validation. Such endeavors will not only validate the efficacy of these models across diverse populations but also pave the way for their integration into clinical practice, ultimately contributing to personalized patient care and improved survival outcomes.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024513350.